



## Urothelial Carcinoma of the Upper Urinary Tract: What Changed?

Guest Editor:

**Prof. Dr. Lukas Lusuardi**

Department of Urology &  
Andrology, Paracelsus Medical  
University Salzburg, 5020  
Salzburg, Austria

Deadline for manuscript  
submissions:

**closed (30 April 2023)**

### Message from the Guest Editor

Upper tract urothelial carcinoma (UTUC) is rare, accounting for just 5–10% of all urothelial tumours. With this Special Issue on UTUC, we would like to focus on some changes and or novelties, which occurred in the last years in uncommon disease.

The tendency to opt for kidney-sparing treatment for UTUC is increasing. Nephro-ureterectomy (RNU) is no longer regarded as the only possible treatment for UTUC, especially in low-grade cancer. Adjuvant treatment is gaining popularity after any type of treatment for UTUC in order to reduce the risk of recurrence and progression.

More research and randomized clinical trials are needed to define which adjuvant systemic therapy could be applied in chronic kidney failure and in histologic variants.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)